Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis

Advances in Experimental Medicine and Biology

Volumn 520, Issue , 2003, Pages 194-202

  Lubberts, Erik ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYTOKINE; CYTOKINE ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ANTAGONIST; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR ANTAGONIST; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 1ALPHA ANTIBODY; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR BLOCKING AGENT; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BONE EROSION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; INFLAMMATION; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0037734215     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0171-8_11     Document Type: Review

References (69)

1. Harris ED, Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322:1277-1289.
2. Miossec P, Chomarat P, Dechanet J. Bypassing the antigen to control rheumatoid arthritis. Immunol Today 1996; 17:170-173.
3. Arend WP. The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40:595-597.
4. Moreland LW, Heck LW, Jr., Koopman WJ. Biologic agents for treating rheumatoid arthritis. Arthritis Rheum 1997; 40:397-409.
5. Müller-Ladner U, Kriegsmann J, Franklin BN et al. Synovial flbroblast of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 49:1607-1615.
6. Franz JK, Pap T, Müller-Ladner U et al. T cell-independent joint destruction. In: Miossec P, Van den Berg WB, Firestein GS, eds. T Cells in Arthritis. Basel: Birkhäuser Verlag, 1998.
7. Firestein GS, Alvaro-Garcia JS, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144:3347-3353.
8. Van de Loo AAJ, Van den Berg WB. Effects of murine recombinant IL-1 on synovial joints in mice: Measurements of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990; 49:238-245.
9. Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and TNF in the rabbit: Evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75:306-310.
10. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis. EMBO Journal 1991; 4025-4031.
11. Georgopoulos S, Plows D, Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996; 46:86-97.
12. Probert L, Plows D, Kontogeorgos G et al. The type I IL-1 receptor acts in serie with TNFα to induce arthritis in TNFα transgenic mice. Eur J Immunol 1995; 25:1794-1797.
13. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-9788.
14. Wooley PH, Dutcher J, Widmer MB et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-6607.
15. Joosten LAB, Helsen MMA, Van de Loo FAJ et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39:797-809.
16. Mori L, Iselin S, de Libero G et al. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type I (TNFRI)-IgGI-treated and TNFRI-deficient mice. J Immunol 1996; 157:3178-3182.
17. Ghivizzani SC, Kang R, Georgescu HI et al. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997; 159:3604-3612.
18. Niki Y, Yadmada H, Kikuchi T et al. Membrane associated IL-1 contributes to chronic synovitis in human IL-1α transgenic mice. Arthritis Rheum 1998; 41:S212.
19. Van den Berg WB, Joosten LAB, Helsen MMA et al. Amelioration of established murine collagen induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95:237-243.
20. Ku G, Faust T, Laufer LL et al. IL-1β converting enzyme inhibition blocks progression of type II collagen induced arthritis in mice. Cytokine 1996; 8:377-386.
21. Bakker AC, Joosten LAB, Arntz OJ et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human IL-1Ra protein in the knee. Arthritis Rheum 1997; 40:893-900.
22. Van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001; 3:18-26.
23. Miossec P, van den Berg WB. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40:2105-2115.
24. McInnes IB, Leung BP, Stuock RD et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nature Med 1997; 3:189-195.
25. McInnes IB, Al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2:175-182.
26. McInnes IB, Liew FY. Interleukin-15: A proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998; 19:75-79.
27. Ogata Y, Kukita A, Kukita T et al. A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2. J Immunol 1999; 162:2754-2760.
28. Ruchatz H, Leung BP, Wei X et al. Soluble IL-15 receptor α-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998; 160:5654-5660.
29. Ziolkowska M, Koch A, Luszczykiewics G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164:2832.
30. Fossiez F, Djossou O, Chomarat P et al. T-cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183:2593.
31. Yao Z, Painter SL, Fanslow WC et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995; 155:5483.
32. Yao Z, Fanslow WC, Seldin MF et al. Herpesvirus Saimiri encodes a new cytokine IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3:811.
33. Chabaud M, Durand JM, Buchs N et al. Human interleukin-17. A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963.
34. Chabaud M, Fossiez F, Taupin JL et al. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161:409.
35. Aarvak T, Chabaud M, Miossec P et al. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162:1246.
36. Chabaud M, Lubberts E, Joosten L et al. IL-17 derived from juxta-articular bone and synovium ontributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001; 3:168-177.
37. Lubberts E, Joosten LAB, Oppers B et al. IL-1 independent role of IL-17 in synovial inflammation and joint destruction during collagen induced arthritis. J Immunol 2001; in press.
38. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345.
39. Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304.
40. Van Bezooijen RL, Farih-Sips HCM, Papapoulos SE et al. Interleukin-17: A new bone acting cytokine in vitro. J Bone Min Res 1999; 14:1513.
41. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin-17 signal transduction. J Exp Med 2000; 191:1233.
42. Quinn JMW, Elliott J, Gillespie MT et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclat formation in vitro. Endocrinology 1998; 139:4424-4427.
43. Fuller K, Wong B, Fox S et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188:997-1001.
44. Burgess TL, Qian Y, Kaufman S et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145:527-538.
45. Jimi E, Akiyama S, Tsurukai T et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999; 163:434-442.
46. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001; 44:253-259.
47. Horwood NJ, Kartsogiannis V, Quinn JMW et al. Activated T cells support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265:144-150.
48. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43:250-258.
49. Takayanagi H, Iizuka H, Juji T et al. Involvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43:259-269.
50. Romas E, Bakharevski O, Hards DK et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000; 43:821-826.
51. Lubberts E, Joosten LAB, Chabaud M et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105:1697-1710.
52. Joosten LAB, Lubberts E, Helsen MMA et al. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol 1997; 159:4094-4102.
53. Gracie AJ, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104:1393.
54. Wei XQ, Leung BP, Arthur HML et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166:517-521.
55. Joosten LAB, Van de Loo FAJ, Lubberts E et al. An IFN-γ-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 2000; 165:6553-6558.
56. Katsikis PD, Chu C-Q, Brennan FM et al. Immuno regulatory role of interleukin-10 (IL-10) in rheumatoid arthritis. J Exp Med 1994; 179:1517-1527.
57. Llorente L, Richaud-Patin Y, Kior R et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37:1647-1655.
58. Cush JJ, Splawski JB, Thomas R et al. Elevated interleukin-10 levels in patient with rheumatoid arthritis. Arthritis Rheum 1995; 38:96-104.
59. Cohen SBA, Katsikis PD, Chu C-Q et al. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum 1995; 38:946-952.
60. Chomarat P, Vannier E, Dechanet J et al. Balance of IL-1 receptor antagonist/IL-1J in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154:1432-1439.
61. Isomäki P, Luukkainen R, Saario R et al. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996; 39:386-395.
62. Joosten LAB, Lubberts E, Durez P et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249-260.
63. Lubberts E, Joosten LAB, Helsen MMA et al Regulatory role of interleukin-10 in joint inflammation and cartilage dstruction in murine streptococcal cell wall arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998; 10:361-369.
64. Lubberts E, Joosten LAB, Van den Bersselaar L et al. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis in the knee and ipsilateral paw. Clin Exp Immunol 2000; 120:375-383.
65. Walmsley M, Katsikis PD, Abney E et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39:495-503.
66. Apparaily F, Verwaerde C, Jacquet C et al. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998; 160:5213-5220.
67. Ma Y, Thornton S, Duwel LE et al. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998; 16:1516-1524.
68. Whalen JD, Lechman EI, Carlos CA et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999; 162:3625-3632.
69. Lubberts E, Joosten LAB, Van den Bersselaar L et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joints of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999; 163:4546-4556.